← Karyopharm Therapeutics Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($109.6m) | ($129.0m) | ($178.4m) | ($199.6m) | ($196.3m) | ($124.1m) | ($165.3m) | ($143.1m) | ($76.4m) | ($196.0m) | — | |
| Depreciation and amortization | $717k | $713k | $735k | $974k | $972k | $789k | $621k | $530k | $340k | $296k | $230k | |
| Amortization of Debt Issuance Costs and Discounts | — | — | $1.4m | $7.2m | $8.1m | $780k | $812k | $814k | $6.4m | $10.5m | — | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | $0 | — | $0 | $0 | $0 | $0 | — | |
| Share-based Payment Arrangement, Noncash Expense | $22.3m | $20.4m | $17.3m | $15.3m | $24.4m | $29.8m | $35.4m | $21.7m | $18.4m | $14.1m | $13.5m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | $39k | — | — | — | — | — | — | — | — | — | — | |
| Share-based Payment Arrangement, Expense | $22.3m | $20.4m | $17.3m | $15.3m | $24.4m | $29.8m | $35.4m | $21.7m | $18.4m | $14.1m | $13.5m | |
| Nonoperating Income (Expense) | $1.3m | $1.6m | $1.5m | ($10.3m) | ($24.1m) | ($25.5m) | ($22.7m) | ($13.2m) | $43.1m | ($105.3m) | — | |
| Other Nonoperating Income (Expense) | $10k | ($81k) | ($33k) | ($50k) | $206k | ($85k) | ($83k) | ($356k) | $28.4m | $152k | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | — | — | — | $7.9m | $5.0m | $9.6m | $5.1m | ($20.1m) | $3.8m | ($4.6m) | $11.9m | |
| Increase (Decrease) in Inventories | — | — | — | $346k | $2.6m | $1.5m | $118k | ($1.2m) | $1.7m | ($701k) | $1.2m | |
| Inventory Write-down | — | — | — | — | $329k | — | — | — | — | — | — | |
| Increase (Decrease) in Accounts Payable | $945k | $909k | ($1.4m) | ($3.3m) | $3.5m | ($2.8m) | $1.2m | $350k | $2.0m | ($1.1m) | ($1.6m) | |
| Net Cash Provided by (Used in) Operating Activities | ($84.4m) |
($73.7m)
+12.65%
|
($159.1m)
-115.85%
|
($190.8m)
-19.93%
|
($160.2m)
+16.03%
|
($107.1m)
+33.15%
|
($149.6m)
-39.62%
|
($92.7m)
+38.00%
|
($127.5m)
-37.49%
|
($75.4m)
+40.88%
|
($59.1m)
+21.57%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $70k | $62k | $2.4m | $206k | $145k | $212k | $118k | $0 | $142k | $0 | ($142k) | |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | — | — | — | — | — | — | $63.7m | — | |
| Payments to Acquire Investments | $134.7m | $98.4m | — | — | — | — | — | — | — | — | ($22.3m) | |
| Net Cash Provided by (Used in) Investing Activities | $24.6m | $17.1m | ($107.7m) | $78.5m | ($53.7m) | $141.8m | ($104.3m) | $7.9m | $95.5m | $43.4m | $31.3m | |
| Cash flows from financing activities: | ||||||||||||
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | — | — | $0 | $0 | $44.7m | ($62.4m) | — | |
| Net Cash Provided by (Used in) Financing Activities | $51.2m |
$75.7m
+48.04%
|
$316.1m
+317.34%
|
$124.3m
-60.68%
|
$172.1m
+38.44%
|
$73.6m
-57.20%
|
$193.7m
+163.06%
|
$1.1m
-99.42%
|
$41.6m
+3605.16%
|
$30.0m
-27.85%
|
$79.8m
+165.74%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | ($66k) | $211k | $49.2m | $12.0m | ($41.6m) | $108.3m | ($60.6m) | ($83.7m) | $9.6m | ($1.9m) | $91.2m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | ($66k) | $211k | $118.7m | $130.7m | $89.1m | $197.4m | $136.9m | $53.2m | $62.8m | $60.9m | $91.2m | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | ($66k) | $211k | ($78k) | $19k | $268k | ($48k) | ($488k) | ($34k) | ($11k) | $20k | $17k | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | $5.2m | $6.0m | $10.4m | $5.2m | $5.2m | $17.1m | $10.7m | — | |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before Tax | $10k | ($62k) | ($27k) | $100k | $300k | — | — | — | — | — | — | |
| General and Administrative Expense | $23.9m | $24.9m | $48.8m | — | — | — | — | — | — | — | — | |
| Income Tax Expense (Benefit) | $139k | $63k | $26k | $40k | $309k | $268k | $369k | $323k | $57k | $43k | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $37.4m | $45.8m | — | |
| Investment Income, Interest | $1.3m | $1.7m | $4.0m | $5.4m | $2.8m | $582k | $2.4m | $10.9m | $7.4m | $2.8m | — | |
| Operating Costs and Expenses | — | — | — | $2.4m | $2.7m | $3.4m | — | — | — | — | — | |
| Operating Expenses | $110.9m | $132.1m | $210.2m | $230.2m | $279.9m | $308.1m | $299.3m | $275.6m | $264.7m | $236.8m | — | |
| Operating Lease, Expense | — | — | — | — | — | — | — | $2.8m | $2.8m | $2.4m | — | |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | — | — | — | $20.0m | — | — | — | — | — |